Frontline treatment of multiple myeloma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The treatment of myeloma has been revolutionized by the availability of new drugs. Combination therapy followed by stem cell transplant holds the promise of ultimately curing a fraction of patients. Objective responses are the norm for induction therapy and up to 50% of patients achieve a complete remission. Ongoing clinical trials continue to address the role of long term maintenance therapy. Understanding the proper management of these agents is paramount to providing patients disease control and yet minimizing side effects from treatment.

Original languageEnglish (US)
JournalHematology
Volume17
Issue numberSUPPL. 1
DOIs
StatePublished - Apr 2012

Fingerprint

Multiple Myeloma
Therapeutics
Stem Cells
Clinical Trials
Transplants
Pharmaceutical Preparations

Keywords

  • Bortezomib
  • Induction
  • Lenalidomide
  • Myeloma
  • Transplant

ASJC Scopus subject areas

  • Hematology

Cite this

Frontline treatment of multiple myeloma. / Fonseca, Rafael.

In: Hematology, Vol. 17, No. SUPPL. 1, 04.2012.

Research output: Contribution to journalArticle

@article{941d1a58cec34797b4e89ddd0d012d9d,
title = "Frontline treatment of multiple myeloma",
abstract = "The treatment of myeloma has been revolutionized by the availability of new drugs. Combination therapy followed by stem cell transplant holds the promise of ultimately curing a fraction of patients. Objective responses are the norm for induction therapy and up to 50{\%} of patients achieve a complete remission. Ongoing clinical trials continue to address the role of long term maintenance therapy. Understanding the proper management of these agents is paramount to providing patients disease control and yet minimizing side effects from treatment.",
keywords = "Bortezomib, Induction, Lenalidomide, Myeloma, Transplant",
author = "Rafael Fonseca",
year = "2012",
month = "4",
doi = "10.1179/102453312X13336169156096",
language = "English (US)",
volume = "17",
journal = "Hematology",
issn = "1024-5340",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Frontline treatment of multiple myeloma

AU - Fonseca, Rafael

PY - 2012/4

Y1 - 2012/4

N2 - The treatment of myeloma has been revolutionized by the availability of new drugs. Combination therapy followed by stem cell transplant holds the promise of ultimately curing a fraction of patients. Objective responses are the norm for induction therapy and up to 50% of patients achieve a complete remission. Ongoing clinical trials continue to address the role of long term maintenance therapy. Understanding the proper management of these agents is paramount to providing patients disease control and yet minimizing side effects from treatment.

AB - The treatment of myeloma has been revolutionized by the availability of new drugs. Combination therapy followed by stem cell transplant holds the promise of ultimately curing a fraction of patients. Objective responses are the norm for induction therapy and up to 50% of patients achieve a complete remission. Ongoing clinical trials continue to address the role of long term maintenance therapy. Understanding the proper management of these agents is paramount to providing patients disease control and yet minimizing side effects from treatment.

KW - Bortezomib

KW - Induction

KW - Lenalidomide

KW - Myeloma

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=84859780337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859780337&partnerID=8YFLogxK

U2 - 10.1179/102453312X13336169156096

DO - 10.1179/102453312X13336169156096

M3 - Article

C2 - 22507793

AN - SCOPUS:84859780337

VL - 17

JO - Hematology

JF - Hematology

SN - 1024-5340

IS - SUPPL. 1

ER -